Drug intelligence / Profile preview

Salucid

Development stage: Unknown
Lead developer: Euro Med Laboratories
Modality: Small Molecules
Administration: Intravenous

Overview

Salucid is a sterile, nonpyrogenic, hypertonic parenteral solution of sodium bicarbonate (typically 8.4% w/v) manufactured by Euro-Med Laboratories. It serves as a systemic alkalinizing agent designed to correct metabolic acidosis by increasing plasma bicarbonate levels, which buffers excess hydrogen ions and restores normal blood pH. It is indicated for the treatment of metabolic acidosis associated with conditions such as cardiac arrest, severe renal disease, uncontrolled diabetes, and circulatory insufficiency. Salucid is administered via intravenous injection and is a critical component in emergency medicine and intensive care for managing severe acid-base imbalances.

Brand names: Salucid
Other names: sodium bicarbonate 8.4% injection

Beyond the preview

Go deeper on Salucid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salucid.

Explore the full profile